NDV-CD278L, when combined with anti-CTLA-4 blockade, induced a significant increase in CD8+ T cells and the upregulation of CD278 and granzyme B. Additionally, this efficacy improved local as well as distant tumor regression in mouse models [90]. The gene discussed is CD8A; the disease is neoplasm.